Division of Thoracic Surgery, Department of Surgery
Cardiovascular Diseases | Endocrine System Diseases | Health Economics | Health Policy | Health Services Administration | Health Services Research | Insurance | Nutritional and Metabolic Diseases | Pharmacoeconomics and Pharmaceutical Economics | Pharmacy Administration, Policy and Regulation
BACKGROUND: Increasing medicines availability and affordability is a key goal of Brazilian health policies. "Farmacia Popular" (FP) Program is one of the government's key strategies to achieve this goal. Under FP, antihypertension (HTN) and antiglycemic (DM) medicines have been provided at subsidized prices in private retail settings since 2006, and free of charge since 2011. We aim to assess the impact of sequential changes in FP benefits on patient affordability and government expenditures for HTN and DM treatment under the FP, and examine their implications for public financing mechanisms and program sustainability.
METHODS: Longitudinal, retrospective study using interrupted time series to analyze: HTN and DM treatment coverage; total and per capita expenditure; percentage paid by MoH; and patient cost sharing. Analyzes were conducted in the dispensing database of the FP program (from 2006 to 2012).
RESULTS: FP has increased its coverage over time; by December 2012 FP covered on average 13% of DM and 11.5% of HTN utilization, a growth of over 600 and 1500%, respectively. The overall cost per treatment to the MoH declined from R$36.43 (R$ = reais, the Brazilian currency) to 18.74 for HTN and from R$33.07to R$15.05 for DM over the period analyzed, representing a reduction in per capita cost greater than 50%. The amount paid by patients for the medicines covered increased over time until 2011, but then declined to zero. We estimate that to treat all patients in need for HTN and DM in 2012 under FP, the Government would need to expend 97% of the total medicines budget.
CONCLUSIONS: FP rapidly increased its coverage in terms of both program reach and proportion of cost subsidized during the period analyzed. Costs of individual HTN and DM treatments in FP were reduced after 2011 for both patients (free) and government (better negotiated prices). However, overall FP expenditures by MoH increased due to markedly increased utilization. The FP is sustainable as a complementary policy but cannot feasibly substitute for the distribution of medicines by the SUS.
Affordability, Diabetes, Government expenditure, Hypertension, Medicines, Non-communicable diseases
Rights and Permissions
© The Author(s). 2020 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
DOI of Published Version
Emmerick ICM, Campos MR, da Silva RM, Chaves LA, Bertoldi AD, Ross-Degnan D, Luiza VL. Hypertension and diabetes treatment affordability and government expenditures following changes in patient cost sharing in the "Farmácia popular" program in Brazil: an interrupted time series study. BMC Public Health. 2020 Jan 8;20(1):24. doi: 10.1186/s12889-019-8095-0. PMID: 31914972; PMCID: PMC6951004. Link to article on publisher's site
BMC public health
Martins Emmerick IC, Campos MR, da Silva RM, Chaves LA, Bertoldi AD, Ross-Degnan D, Luiza VL. (2020). Hypertension and diabetes treatment affordability and government expenditures following changes in patient cost sharing in the "Farmacia popular" program in Brazil: an interrupted time series study. Surgery Publications. https://doi.org/10.1186/s12889-019-8095-0. Retrieved from https://escholarship.umassmed.edu/surgery_pp/183
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Cardiovascular Diseases Commons, Endocrine System Diseases Commons, Health Economics Commons, Health Policy Commons, Health Services Administration Commons, Health Services Research Commons, Insurance Commons, Nutritional and Metabolic Diseases Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons